Pimobendan hydrochloride is used as a selective PDE3 inhibitor for the treatment of heart failure; it enhances cardiac contractility by increasing L-type calcium current in human and rabbit atrial cells; it demonstrates beneficial effects on survival in a murine model of EMC virus-induced myocarditis; it reduces myocardial cellular infiltration, intracardiac TNF-α and IL-1β levels, and suppresses iNOS gene expression and NO production in the heart.